Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NYMXF Alzheimer's treatment! -- Ignore unavailable to you. Want to Upgrade?

To: Demetre Deliyanakis who wrote (123)	8/25/1998 3:31:00 PM
From: Ron	Read Replies (1) \| Respond to of 132

MORE on NYMXF Alzheimers test: ROCKVILLE, Md.--(BUSINESS WIRE)--August 25, 1998--Nymox Pharmaceutical Corporation (NASDAQ National Market: NYMXF; Montreal Exchange: NMX) announced today that it has significantly advanced the process in its cell biology laboratories for one of its key screening models for selecting and developing new Alzheimer's disease (AD) drug candidates. This AD7C screening model has unique properties which make it highly relevant to AD. The system is being used by Nymox's Pharmaceutical Division to further extend the pipeline of candidate drugs for neurodegenerative diseases such as AD. The model is based on human neuronal cells which have the AD7C-NTP gene inserted into them and where this gene has become an integral part of the cell. The cells produce AD7C-NTP, subsequently start the process of neuronal sprouting, going through a degenerative process, and then finally die by apoptosis. This sequence of cellular events very closely mimics what is known to occur in the degenerating neurons in the brains of Alzheimer patients. The AD7C screening system is distinct compared with the Company's other drug development programs (such as spheron targeted therapies). biz.yahoo.com